RecruitingNot ApplicableNCT06356727

Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling

Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling in Idiopathic Dilated Cardiomyopathy


Sponsor

Azienda Ospedaliera Universitaria Integrata Verona

Enrollment

190 participants

Start Date

Jan 3, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF \<40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria3

  • Male or female, aged \>18 years
  • First diagnosis of idiopathic DCM (defined according to the most recent ESC Guidelines) with LVEF ≤ 40% and clinical indication to diagnostic coronary angiography
  • Willing and able to give informed consent for participation in the study

Exclusion Criteria15

  • Obstructive CAD (defined as angiographically intermediate disease \[50%-70%\] with impaired FFR or as angiographically severe disease \[\>70%\] in 1 or more epicardial vessels)
  • History of previous myocardial infarction, percutaneous revascularization or coronary-aortic bypass graft (CABG) surgery
  • Valvular heart disease (rheumatic heart disease, severe aortic stenosis, severe aortic regurgitation, severe primary mitral regurgitation)
  • Infective endocarditis
  • Congenital heart disease
  • Peripartum cardiomyopathy
  • Acute myocarditis (detected by endomyocardial biopsy - histological criteria - or by CMR - Lake Louis criteria) and pericarditis
  • Persistent tachyarrhythmias (documented persistent high-rate supraventricular arrhythmias)
  • Excessive alcohol intake (\>80 g/die for at least five years)
  • History of chemotherapy (anthracycline therapy, cumulative dosages \>250 mg/m2)
  • History of uncontrolled arterial hypertension (blood pressure \>160/100 mmHg)
  • Stage IV and V of chronic kidney disease (eGFR \< 30 ml/min, estimated through CKD - EPI Creatinine Equation)
  • Allergy or other contraindication to iodinated contrast and/or adenosine
  • Chronic resting O2 saturation \<85%
  • Pregnancy or suspected pregnancy

Interventions

DIAGNOSTIC_TESTThermodilution based assessment of coronary microcirculation

Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.


Locations(9)

Azienda Ospedaliera Universitaria di Ferrara

Ferrara, Italy

Cardiothoracic and Vascular Department (DICATOV) IRCCS, Ospedale Policlinico San Martino

Genova, Italy

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) dell'Ospedale San Raffaele

Milan, Italy

Ospedale Galeazzi di Sant'Ambrogio IRCCS

Milan, Italy

University of Naples Federico II

Naples, Italy

Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, Italy

Azienda Ospedaliero-Universitaria Sant'Andrea

Rome, Italy

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

Torino, Italy

Azienda Ospedaliera Universitaria di Verona

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06356727


Related Trials